Hsu HC, et al. - In a study sample of patients treated for metastatic colorectal cancer (mCRC; n=102), researchers assessed the clinical outcomes related to different sequences of biological therapies used as first- and third-line therapy in these patients. In this retrospective study, only cases treated with cetuximab, bevacizumab, and standard chemotherapy for wild-type KRAS exon 2 mCRC were included. The participants had received cetuximab or bevacizumab as first- or third-line therapy combined with a similar chemotherapy backbone. Favorable clinical outcomes were reported in relation to first-line cetuximab therapy followed by third-line bevacizumab therapy vs the reverse sequence.